InvestorsHub Logo
Followers 40
Posts 2492
Boards Moderated 0
Alias Born 04/07/2012

Re: JenningsB post# 458

Tuesday, 06/13/2017 1:44:49 PM

Tuesday, June 13, 2017 1:44:49 PM

Post# of 638
Actually
The positives far outweigh the negatives here.
The recurrence rate for posterior segment uveitis was halved.

The cost was higher IOP that required medication (no surgery).

You will see this getting approved in both Europe and the US.

This is a pullback fueled by ignorance.

I'm buying more here!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EYPT News